A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

NCT05530655 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Radiation Toxicity
Urinary Complication

Interventions

DRUG: Lisinopril Tablets

Sponsor

University of Rochester

Collaborators

[object Object]